Frank Alexander Hamill

Frank Alexander Hamill

Auto-generated profile, based on publicly available information

Frank Alexander Hamill

Global Engagement Program, MRIGlobal, Gaithersburg, Maryland

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2005 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
GMGail Mahady
Gail Mahady
SPSusan L. Pendland
Susan L. Pendland
ASAdenia Stoia
Adenia Stoia
FHFrank A. Hamill
Frank A. Hamill
DFDaniel Fabricant
Daniel Fabricant
LCLucas R. Chadwick
Lucas R. Chadwick

1 January 2003 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
FHF.A Hamill
F.A Hamill
SAS Apio
S Apio
NMN.K Mubiru
N.K Mubiru
RBR Bukenya-Ziraba
R Bukenya-Ziraba
MMM Mosango
M Mosango
DSD.D Soejarto
D.D Soejarto

1 July 2000 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
FHF.A. Hamill
F.A. Hamill
SAS. Apio
S. Apio
NMN.K. Mubiru
N.K. Mubiru
MMM. Mosango
M. Mosango
RBR. Bukenya-Ziraba
R. Bukenya-Ziraba
DSD.D. Soejarto
D.D. Soejarto

1 January 2008
Verified
Journal Article
Closed access
LSLeanna J Standish
Leanna J Standish
CTCarolyn Torkelson
Carolyn Torkelson
FHFrank A Hamill
Frank A Hamill
DYDaesong Yim
Daesong Yim
AHAlicia Hill-Force
Alicia Hill-Force
MMMark R Martzen
Mark R Martzen

1 July 2003 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
FHF.A Hamill
F.A Hamill
SAS Apio
S Apio
NMN.K Mubiru
N.K Mubiru
MMM Mosango
M Mosango
RBR Bukenya-Ziraba
R Bukenya-Ziraba
DSD.D Soejarto
D.D Soejarto

22 October 2021 in African Journal of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
LPLance D. Presser
Lance D. Presser
JCJeanette Coffin
Jeanette Coffin
LKLamine Koivogui
Lamine Koivogui
ACAllan Kevin Olayemi Campbell
Allan Kevin Olayemi Campbell
JCJulian Campbell
Julian Campbell
SKStephen Krcha
Stephen Krcha
Background: Ebola virus emerged in West Africa in December 2013. The ease of mobility, porous borders, and lack of public health infrastructure led to the largest Ebola virus disease (EVD) outbreak to date. Intervention: The 2013 EVD outbreak signalled the need for laboratory diagnostic capabilities in areas without strong public health systems. As part of the United States’ Department of Defense response, MRIGlobal was contracted to design, fabricate, equip, deploy, and operate two mobile diagnostic laboratories (MDLs). The first laboratory analysed blood samples from patients in an adjacent Ebola Treatment Centre (ETC) and buccal swabs from the deceased in the community in Moyamba, Sierra Leone. The second laboratory was deployed to support an ETC in Conakry, Guinea. The Department of Defense provided real-time quantitative reverse transcription polymerase chain reaction assays that were deployed and validated on-site. Lessons Learnt: Prompt and accurate molecular diagnostics reduced sample turn-around times from over 24 h to under 4 h. Experienced laboratory staff tested up to 110 samples per day and on-site engineering proved necessary for MDL setup and operation. As the Ebola response slowed, the sustainment of the MDLs’ operations was prioritised, including staff training and the transition of the MDLs to local governments. Training programmes for local staff were prepared in Sierra Leone and Guinea. Recommendations: The MRIGlobal MDL team significantly contributed to establishing increased laboratory capacity during the EVD outbreak in West Africa. Using the MDLs for molecular diagnosis is highly recommended until more sustainable solutions can be provided.